23 September 2022 in The Lancet Regional Health - Americas
Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster. School of Medicine, UC-Chile and ANID. ClinicalTrials.gov ID: NCT05124509
6 October 2022 in Transplantation Proceedings
1 January 2025 in Translational Gastroenterology and Hepatology
Background: Living donor selection is crucial to minimize postoperative donor complications and to improve recipient outcomes. This study describes the selection process and evaluates the reasons for discarding potential donors in our living donor liver transplantation (LDLT) program. Methods: Retrospective descriptive analysis from all potential donors evaluated in our LDLT program between April 2018 and July 2021. Selection criteria included age 18–60 years old, no significant medical or mental comorbidities, ABO and anatomical suitability. Results: A total of 231 potential donors were evaluated. Mean age was 37.2±11.1 years and male gender in 51.9%. One hundred and one potential donors (43.7%) did not complete the evaluation, mainly because of availability of a deceased donor during the process (n=32; 13.9%), ABO incompatibility (n=14; 6.1%), progression or death of the recipient (n=20; 8.7%). Of the 130 who completed their radiological evaluation, 55 (42.3%) were anatomically unsuitable, mainly due to small liver remnant size (n=25/130; 19.2%) and steatosis (n=17/130; 13.1%). Out of the 231 potential donors, 75 were accepted as adequate donors (32.5%) and 36 candidates underwent liver donation (15.6%). Conclusions: Only one-third of all potential donors are suitable for donation and half of them will undergo surgery. Given that in our setting computed tomography (CT) has a lower cost than magnetic resonance imaging (MRI), starting with a CT scan decreases the high cost of further workup of donors that are not anatomically suitable for living liver donation.
18 January 2025 in Revista de Cirugía
Introducción. El trasplante hepático con donante vivo (THDV) es una técnica quirúrgica desarrollada para enfrentar la baja tasa de donación. La selección del donante es crucial para minimizar los riesgos del donante y maximizar los resultados del receptor. La volumetría hepática derecha mediante tomografía computada (VTCHD) es uno de los pasos más importantes al planificar la hepatectomía derecha donante vivo (HDDV). Métodos. Estudio retrospectivo de todos los pacientes sometidos a HDDV en HCUC, entre enero 2016-diciembre 2021. Se compararon VTCHD y VTCHD corregida (VTCHDc) con peso del injerto (PI) mediante cálculo de diferencia de medias, utilizando t de student para muestras pareadas, el cálculo del coeficiente de correlación de Pearson para evaluar correlación lineal y test de Bland-Altman (BA) y cálculo de coeficiente de correlación intraclase (CCI) para evaluar concordancia. Resultados. 41 pacientes fueron sometidos a HDDV, de éstos 36 tenían VTCHD. El promedio VTCHD y VTCHDc fue 902,7 ± 162 cc y 739,9 ± 132,8 cc, respectivamente. El promedio PI fue 773,8 ± 126,9 cc. El promedio VTCHD fue significativamente superior al del PI (16.7% de sobre-estimación. El promedio VTCHDc persistió siendo diferente al del PI (4.4% de sub-estimación). Existió correlación lineal directa entre VTC y PI al calcular coeficiente de correlación de Pearson (r=0,796; p<0,001). El GBWR promedio calculado con PI estimado con VTCHD fue 1.27. El GBWR promedio con PI real fue 1.05.Discusión y conclusión. El cálculo de VTCHD con factor de corrección tiene buena correlación y concordancia con el peso del injerto posterior a HDDV.